Arcellx (ACLX)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$7.73 (-8.08%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Arcellx (ACLX)
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.

Key Insights

Critical company metrics and information
  • Share Price

    $89.17
  • Market Cap

    $4.82 Billion
  • Total Outstanding Shares

    54.08 Million Shares
  • Total Employees

    130
  • Dividend

    No dividend
  • IPO Date

    February 4, 2022
  • SIC Description

    Biological Products, (no Disgnostic Substances)
  • Homepage

    https://www.arcellx.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow, Continuing$33.42 Million
Net Cash Flow From Investing Activities$-157.91 Million
Net Cash Flow From Operating Activities$20.81 Million
Net Cash Flow From Operating Activities, Continuing$20.81 Million
Net Cash Flow From Investing Activities, Continuing$-157.91 Million
Net Cash Flow From Financing Activities, Continuing$170.52 Million
Net Cash Flow$33.42 Million
Net Cash Flow From Financing Activities$170.52 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Basic Average Shares$160.38 Million
Operating Expenses$225.24 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Preferred Stock Dividends And Other Adjustments$0.00
Income Tax Expense/Benefit$1.19 Million
Income/Loss From Continuing Operations After Tax$-40.42 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Net Income/Loss Available To Common Stockholders, Basic$-40.42 Million
Net Income/Loss Attributable To Parent$-40.42 Million
Other Operating Expenses$82.01 Million
Revenues$155.82 Million
Operating Income/Loss$-69.42 Million
Research and Development$141.23 Million
Income/Loss From Continuing Operations Before Tax$-39.24 Million
Diluted Earnings Per Share$0.71
Costs And Expenses$195.06 Million
Benefits Costs and Expenses$195.06 Million
Diluted Average Shares$160.38 Million
Net Income/Loss$-40.42 Million
Basic Earnings Per Share$0.71

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Equity$483.02 Million
Other Current Liabilities$131.03 Million
Noncurrent Liabilities$144.87 Million
Noncurrent Assets$177.61 Million
Current Liabilities$137.02 Million
Liabilities And Equity$764.91 Million
Equity Attributable To Noncontrolling Interest$0.00
Liabilities$281.89 Million
Assets$764.91 Million
Other Non-current Assets$130.11 Million
Accounts Payable$5.99 Million
Current Assets$587.30 Million
Equity Attributable To Parent$483.02 Million
Fixed Assets$47.50 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.